What can patients tell us in Sjögren's syndrome?

被引:1
|
作者
Berry, Joe [1 ]
Tarn, Jessica [1 ]
Lendrem, Dennis [1 ]
Casement, John [1 ]
Ng, Wan-Fai [1 ,2 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, England
[2] Natl Inst Hlth & Care Res NIHR, Newcastle Biomed Res Ctr, Newcastle Upon Tyne, England
[3] Newcastle upon Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, England
来源
关键词
Sj & ouml; gren's; patient-reported outcomes; electronic patient-reported outcomes; stratified medicine; heterogeneity; newcastle Sj & ouml; gren's stratification tool; endotypes; composite endpoints; REPORTED OUTCOME MEASURES; SJOGRENS-SYNDROME;
D O I
10.1515/rir-2024-0004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In Sj & ouml;gren's Syndrome (SS), clinical heterogeneity and discordance between disease activity measures and patient experience are key obstacles to effective therapeutic development. Patient reported outcome measures (PROMs) are useful tools for understanding the unmet needs from the patients' perspective and therefore they are key for the development of patient centric healthcare systems. Initial concern about the subjectivity of PROMs has given way to methodological rigour and clear guidance for the development of PROMs. To date, several studies of patient stratification using PROMs have identified similar symptom-based subgroups. There is evidence to suggest that these subgroups may represent different disease endotypes with differing responses to therapeutic interventions. Stratified medicine approaches, alongside sensitive outcome measures, have the potential to improve our understanding of SS pathobiology and therapeutic development. The inclusion of PROMs is important for the success of such approaches. In this review we discuss the opportunities of using PROMs in understanding the pathogenesis of and therapeutic development for SS.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 50 条
  • [1] Lung involvement in patients with primary Sjögren’s syndrome: what are the predictors?
    Veli Yazisiz
    Gokhan Arslan
    İrem Hicran Ozbudak
    Sema Turker
    Funda Erbasan
    Ali Berkant Avci
    Omer Ozbudak
    Ender Terzioglu
    Rheumatology International, 2010, 30 : 1317 - 1324
  • [2] Sjögren’s syndrome
    Geza Balint
    W. Watson Buchanan
    Colin A. Kean
    Walter Kean
    K. D. Rainsford
    Inflammopharmacology, 2024, 32 : 37 - 43
  • [3] Sjögren’s syndrome in patients with ankylosing spondylitis
    Senol Kobak
    Arzu Celebi Kobak
    Yasemin Kabasakal
    Eker Doganavsargil
    Clinical Rheumatology, 2007, 26 : 173 - 175
  • [5] Muscarinics for Xerostomia in Patients with Sjögren’s Syndrome
    Martin M. Ferguson
    Clinical Drug Investigation, 2002, 22 (9) : 639 - 640
  • [6] Sjögren-SyndromSjögren’s syndrome
    Torsten Witte
    Zeitschrift für Rheumatologie, 2019, 78 : 511 - 517
  • [7] Sjögren-SyndromSjögren’s syndrome
    T. Witte
    Zeitschrift für Rheumatologie, 2014, 73 : 49 - 61
  • [8] Meibomian gland dropout in Sjögren’s syndrome and non-Sjögren’s dry eye patients
    Siwen Zang
    Ying Cui
    Yang Cui
    Wenlei Fei
    Eye, 2018, 32 : 1681 - 1687
  • [9] Vasculitis in Sjögren’s Syndrome
    R. Hal Scofield
    Current Rheumatology Reports, 2011, 13 : 482 - 488
  • [10] The management of Sjögren's syndrome
    Clio P Mavragani
    Niki M Moutsopoulos
    Haralampos M Moutsopoulos
    Nature Clinical Practice Rheumatology, 2006, 2 : 252 - 261